CAR T-cell Therapy

Kami Maddocks, MD, discusses the significance of the selinexor approval in the diffuse large B-cell lymphoma treatment paradigm, emerging strategies that seek to address unmet needs, and remaining sequencing questions.

Lori A. Leslie, MD, discusses developments in CAR T-cell therapy in diffuse large B-cell lymphoma and mantle cell lymphoma.

The investigational CAR T-cell product AUTO3 in combination with pembrolizumab was found to have a tolerable safety profile and elicit durable complete responses in patients with relapsed/refractory diffuse large B-cell lymphoma.

Jeffrey Zonder, MD, discusses the ZUMA-2 trial in mantle cell lymphoma and the ZUMA-5 trial in indolent non-Hodgkin lymphoma.

Abhinav Deol, MD, discusses the nuances of utilizing CAR T-cell therapy in lymphoma and leukemia.

The FDA has granted a priority review designation to a biologics license application for idecabtagene vicleucel for the treatment of adult patients with multiple myeloma who have received at least 3 previous therapies.

Luciano J. Costa, MD, PhD, discusses the promising role of CAR T-cell therapy in relapsed/refractory multiple myeloma.

Brian T. Hill, MD, PhD, discusses the role of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.

Luciano J. Costa, MD, PhD, discusses remaining challenges with investigational CAR T-cell therapies in relapsed/refractory multiple myeloma.

A supplemental biologics license application has been filed with the FDA for axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma and marginal zone lymphoma following 2 or more previous lines of systemic therapy.

Nina Shah, MD, discusses the phase 1/2 EVOLVE study with orvacabtagene autoleucel in relapsed/refractory multiple myeloma.

Pashna N. Munshi, MD, discusses the CAR T-cell therapies that have emerged in the lymphoma space and highlights the next steps for research with these products.

Luciano J. Costa, MD, discusses the emerging role of CAR T-cell therapy in relapsed/refractory multiple myeloma, investigational products such as ide-cel, orva-cel, and JNJ-4528, and early intervention strategies to manage the toxicities associated with these products.

The FDA has placed a clinical hold on the phase 1 P-PSMA-101-001 trial examining the autologous CAR T-cell therapy P-PSMA-101 in patients with metastatic castration-resistant prostate cancer.

Sattva Neelapu, MD, discussed findings from the first-in-human phase 1 ALPHA study which demonstrated encouraging short-term efficacy, along with manageable toxicities, with ALLO-501 and ALLO-647.

Nina Shah MD, discusses the future of CAR T-cell therapy and bispecific antibodies in multiple myeloma.

Nina Shah, MD, discusses ​ongoing research with BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma.

Nina Shah, MD, discusses the updated efficacy findings of JNJ-4528 from the phase 1b/2 CARTITUDE-1 study in relapsed/refractory multiple myeloma.

Nina Shah, MD, discusses the future of CAR T-cell therapy in multiple myeloma. 

Jae Park, MD, discusses ​the benefits of off-the-shelf CAR T-cell therapy in acute lymphoblastic leukemia.

Jae Park, MD, discusses considerations for CAR T-cell therapy in relapsed/refractory acute lymphoblastic leukemia.

Muhammad Bilal Abid, MD, MRCP, discusses challenges with CAR-T cell therapy during the coronavirus disease 2019 pandemic.

A CD30-targeted CAR T-cell therapy was found to elicit a high rate of durable complete responses (CRs) in heavily pretreated patients with relapsed/refractory Hodgkin lymphoma.

Paul J. Shaughnessy, MD, discusses the challenges faced with CAR T-cell therapy in hematologic malignancies.

Paul J. Shaughnessy, MD, discusses how CAR T-cell therapy is being utilized in hematologic malignancies, challenges faced with this modality, and ongoing research efforts being made to better leverage its use.